Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

QLQing LiYWYu Wu

Discussion

Loading...

Member takes

Overview

Phase II trial reveals a 53.8% complete remission rate in relapsed AML with chidamide and hypomethylating agents, highlighting the potential of venetoclax.

Key Points

  • Evaluate the efficacy and safety of chidamide combined with hypomethylating agents in relapsed/refractory acute myeloid leukemia.
  • Multicenter, prospective phase II study
  • Combination regimens evaluated in patients with R/R AML
  • Historical control group used for comparison
  • Complete remission rate was 53.8% among all patients
  • CR rate was 37.5% for dual therapy with chemotherapy
  • CR rate was 80% for dual therapy with venetoclax

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d318https://doi.org/10.1182/blood-2025-6982
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study2025
  2. 2Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia2025
  3. 3Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML2025
  4. 4Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity2025
  5. 5Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway2025